Policy Implications of Artificial Intelligence and Machine Learning in Diabetes Management

Curr Diab Rep. 2020 Feb 1;20(2):5. doi: 10.1007/s11892-020-1287-2.


Purpose of review: Machine learning (ML) is increasingly being studied for the screening, diagnosis, and management of diabetes and its complications. Although various models of ML have been developed, most have not led to practical solutions for real-world problems. There has been a disconnect between ML developers, regulatory bodies, health services researchers, clinicians, and patients in their efforts. Our aim is to review the current status of ML in various aspects of diabetes care and identify key challenges that must be overcome to leverage ML to its full potential.

Recent findings: ML has led to impressive progress in development of automated insulin delivery systems and diabetic retinopathy screening tools. Compared with these, use of ML in other aspects of diabetes is still at an early stage. The Food & Drug Administration (FDA) is adopting some innovative models to help bring technologies to the market in an expeditious and safe manner. ML has great potential in managing diabetes and the future is in furthering the partnership of regulatory bodies with health service researchers, clinicians, developers, and patients to improve the outcomes of populations and individual patients with diabetes.

Keywords: Artificial intelligence; Diabetes; Diabetic retinopathy; Diagnosis; Machine learning; Management.

Publication types

  • Review

MeSH terms

  • Artificial Intelligence / legislation & jurisprudence
  • Diabetes Mellitus / diagnosis*
  • Diabetes Mellitus / therapy*
  • Health Policy / legislation & jurisprudence*
  • Humans
  • Machine Learning / legislation & jurisprudence*
  • Mass Screening / legislation & jurisprudence
  • United States
  • United States Food and Drug Administration